ଏଞ୍ଜାଲୁଟାମାଇଡ

ଏଞ୍ଜାଲୁଟାମାଇଡ
Clinical data
Pronunciation	/ɛksˈtændi/ eks-TAN-dee
Trade names	Xtandi
Synonyms	MDV-3100; ASP-9785
AHFS/Drugs.com	monograph
MedlinePlus	a612033
data	EU EMA: yes; US DailyMed: Enzalutamide;
Pregnancy; category	AU: X (High risk) ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	Rats: 89.7%; Humans: unknown (but at least 84.6% based on recovery from excretion)
Protein binding	Enzalutamide: 97–98% (primarily to albumin); NDME: 95%
Metabolism	Liver (primarily CYP2C8 and CYP3A4)
Metabolites	• NDME (active); • Carboxylic acid derivative metabolite (inactive)
Elimination half-life	Enzalutamide: 5.8 days (range 2.8–10.2 days); NDME: 7.8–8.6 days
Excretion	Urine: 71.0%; Bile: 13.6%; Feces: 0.39%
Identifiers
	IUPAC name 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide;
ECHA InfoCard	100.231.722
Chemical and physical data
Formula	C21H16F4N4O2S
Molar mass	୪୬୪.୪୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C;
	InChI InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30); Key:WXCXUHSOUPDCQV-UHFFFAOYSA-N;

,

ଏଞ୍ଜାଲୁଟାମାଇଡ, ଏକ ବିକ୍ରୟ ନାମ ଟାଣ୍ଡି (Xtandi) ହେଉଛି ପ୍ରୋଷ୍ଟେଟ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୨] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହାକାଷ୍ଟ୍ରେସନ୍-ପ୍ରତିରୋଧକ ପ୍ରୋଷ୍ଟେଟ୍ କର୍କଟ (mCRPC), ଏବଂ ମେଟାଷ୍ଟାଟିକ୍ କାଷ୍ଟ୍ରେସନ୍ -ସମ୍ବେଦନଶୀଳ ପ୍ରୋଷ୍ଟେଟ୍ କର୍କଟ (mCSPC)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହୃତ ହୁଏ ।^[୨] ଏହା ପାଟିଦ୍ୱାରା ନିଆଯାଏ | ^[୨]

ଅଣସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କା, ପିଠି ଯନ୍ତ୍ରଣା, ତରଳ ଝାଡ଼ା, ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, ଉଚ୍ଚ ରକ୍ତଚାପ ଏବଂ ଗରମ ଫ୍ଲସ ଅନ୍ତର୍ଭୁକ୍ତ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାତ, ପୃଷ୍ଠଭଗ ରିଭର୍ସିବଲ୍ ଏନସେଫାଲୋପାଥି ସିଣ୍ଡ୍ରୋମ, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଏବଂ ଦୁର୍ଘଟଣା ପତନ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର, ପୁରୁଷଙ୍କ ସମେତ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୨] ଏହାର ଅନେକ ପାରଷ୍ପରିକ ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ ।^[୨] ଏହା ଏକ ଅଣ-ଷ୍ଟେରଏଡାଲ୍ ଆଣ୍ଟିଆଣ୍ଡ୍ରୋଜେନ୍ (NSAA) ଯାହା ଟେଷ୍ଟୋଷ୍ଟେରନ୍ ପରି ଆଣ୍ଡ୍ରୋଜେନକୁ ଆଣ୍ଡ୍ରୋଜେନ୍ ରିସେପ୍ଟର ସ‌ହିତ ବନ୍ଦନ‌କୁ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୋଇଥାଏ ।^[୬]

ଏଞ୍ଜାଲୁଟାମାଇଡ ୨୦୦୬ ମସିହାରେ ପେଟେଣ୍ଟ୍ ହୋଇଥିଲା ଏବଂ ୨୦୧୨ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା।^[୭] ^[୬] ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଲିପିବଦ୍ଧ ଅଛି ।^[୮] ଯୁକ୍ତରାଜ୍ୟରେ ୪ ସପ୍ତାହ ଚିକିତ୍ସା ବାବଦ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୨୭୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୨,୦୦୦ ଡଲାର ଅଟେ ।^[୧୦]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ "Enzalutamide (Xtandi) Use During Pregnancy". Drugs.com. 4 September 2018. Archived from the original on 22 December 2019. Retrieved 21 December 2019.
↑ ^୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ ^୨.୧୦ ^୨.୧୧ ^୨.୧୨ ^୨.୧୩ "Xtandi- enzalutamide capsule". DailyMed. 9 July 2018. Archived from the original on 20 December 2015. Retrieved 21 December 2019.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J (2015). "Clinical Pharmacokinetic Studies of Enzalutamide". Clin Pharmacokinet. 54 (10): 1043–55. doi:10.1007/s40262-015-0271-5. PMC 4580721. PMID 25917876.
↑ Kim TH, Jeong JW, Song JH, Lee KR, Ahn S, Ahn SH, Kim S, Koo TS (November 2015). "Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats". Archives of Pharmacal Research. 38 (11): 2076–82. doi:10.1007/s12272-015-0592-9. PMID 25956695. S2CID 26903608.
↑ Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP (2016). "Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide". Clin Pharmacokinet. 55 (11): 1369–1380. doi:10.1007/s40262-016-0403-6. PMC 5069300. PMID 27106175.
↑ ^୬.୦ ^୬.୧ "Enzalutamide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 December 2019. Retrieved 15 December 2021.
↑ Sawyers, Charles; Jung, Michael; Chen, Charlie; Ouk, Samedy; Welsbie, Derek; Tran, Chris; Wongvipat, John; Yoo, Dongwon (4 January 2007). "Diarylhydantoin compounds" (in ଇଂରାଜୀ). Archived from the original on 5 October 2016. Retrieved 15 December 2021.
↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 991. ISBN 978-0857114105.
↑ "Xtandi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 December 2021. Retrieved 15 December 2021.

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Enzalutamide (Xtandi) Use During Pregnancy". Drugs.com. 4 September 2018. Archived from the original on 22 December 2019. Retrieved 21 December 2019.

[PI2021-2] ୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ ^୨.୧୦ ^୨.୧୧ ^୨.୧୨ ^୨.୧୩ "Xtandi- enzalutamide capsule". DailyMed. 9 July 2018. Archived from the original on 20 December 2015. Retrieved 21 December 2019.

[pmid25917876-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J (2015). "Clinical Pharmacokinetic Studies of Enzalutamide". Clin Pharmacokinet. 54 (10): 1043–55. doi:10.1007/s40262-015-0271-5. PMC 4580721. PMID 25917876.

[pmid25956695-4] Kim TH, Jeong JW, Song JH, Lee KR, Ahn S, Ahn SH, Kim S, Koo TS (November 2015). "Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats". Archives of Pharmacal Research. 38 (11): 2076–82. doi:10.1007/s12272-015-0592-9. PMID 25956695. S2CID 26903608.

[pmid27106175-5] Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP (2016). "Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide". Clin Pharmacokinet. 55 (11): 1369–1380. doi:10.1007/s40262-016-0403-6. PMC 5069300. PMID 27106175.

[AHFS2021-6] ୬.୦ ^୬.୧ "Enzalutamide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 December 2019. Retrieved 15 December 2021.

[Patent2006-7] Sawyers, Charles; Jung, Michael; Chen, Charlie; Ouk, Samedy; Welsbie, Derek; Tran, Chris; Wongvipat, John; Yoo, Dongwon (4 January 2007). "Diarylhydantoin compounds" (in ଇଂରାଜୀ). Archived from the original on 5 October 2016. Retrieved 15 December 2021.

[WHO22nd-8] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[BNF81-9] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 991. ISBN 978-0857114105.

[10] "Xtandi Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 December 2021. Retrieved 15 December 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]